Roche’s Women as Visionaries in Eyecare (#WAVE) initiative connects women in ophthalmology whose work, experience and ambition are helping shape eyecare. If you’re at #EURETINA2026, join us at the Roche booth for inspiring talks and to connect with a community working to move the NA26

At Roche our commitment to #BreastCancer research has been guided by science and a dedication to improving outcomes for people living with cancer. 🧵👇

We continue to focus our scientific efforts on areas of high unmet need, aiming to translate research insights into meaningful health solutions.

HR-positive #BreastCancer is the most common subtype, but early-stage recurrence and progression following initial therapies remain a reality for many.
Together, we’re working to help change this.

To move retinal care forward, we must understand how solutions perform in everyday practice.

As @EURETINA 2026 continues, Nilesh Mehta, Therapeutic Area Head, Ophthalmology at Roche, is sharing what our latest real-world evidence could mean for patients with neovascular eneration (#nAMD) and diabetic macular edema (#DME).

#EURETINA26

#MEDIA – We are pleased that the New England Journal of Medicine has published phase III data demonstrating significant progression-free survival benefit with our investigational medicine for people with ER-positive advanced #BreastCancer.

Read more zugQ7

$ROG $RHHBY

Expanding the possible starts with fresh ideas, emerging leaders and new perspectives. The Leading Edge Incubator (LEI) is designed to empower the next generation shaping the future of ophthalmology.

Attending #EURETINA26? Stop by the Roche booth to meet current LEI members and from the 2025-26 cohort.

#EURETINA2026

#MEDIA – At #EURETINA2026, we’re pleased to share new real-world data confirming effectiveness and safety across major retinal conditions, including nAMD, DME and RVO.

#MEDIA – We are pleased that the U.S. FDA has accepted the new drug application for our investigational medicine for both relapsing and primary progressive multiple sclerosis.

Read here 👉 spkl.io/60187p5Iw

#multiplesclerosis #MS

Weak circulating tumor DNA (ctDNA) signals remain a primary bottleneck in minimal residual disease research. Roche’s sequencing by expansion (SBX) achieves the throughput necessary to bypass standard resolution limits. Discover more: go.roche.com/xsbxgen2

(Research use only)
tion #MakeSpaceWithSBX #RocheSBX

Better cancer outcomes shouldn't demand bigger budgets—they demand smarter innovation.

Reflecting on this year's World Cancer Congress, the path forward is clear: the real cost of cancer isn’t just treatment, but the time stolen from families when care comes too late.

By agnosis and care closer to home, we don't just free up hospital capacity. We change the equation entirely—turning progress into healthy years of life.

#WhatsItWorth #WCC2026 #GlobalHealth

Breast cancer care shouldn't depend on where you live.

At this year's World Cancer Congress, the message was clear: regional collaboration is key to ensuring every woman gets the care she deserves, no matter where she lives.

By working across borders to bring diagnosis and e, we can turn progress into time—time for women to keep pursuing their dreams.

#WhatsItWorth #WCC2026 #GlobalHealth

#MEDIA – We are excited to share positive interim phase III results in IgA nephropathy, a progressive kidney disease that can lead to kidney failure.

Read more here 👉 spkl.io/60157TnLZ

$ROG $RHHBY

We are pleased to share positive topline Phase II results from our investigational dual GLP-1/GIP receptor agonist in people living with type 2 diabetes, obesity or overweight. Read more here: spkl.io/60197Tn6V $ROG $RHHBY #Obesity

#MEDIA - We are pleased to share that the European Commission (EC) has approved our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD), offering an alternative to standard-of-care eye injections. roche.com/media

#MEDIA –The CHMP has recommended approval of our multiple sclerosis treatment for young people aged 10+ living with relapsing MS in the EU, who have limited options today.

👉spkl.io/60107T3w4

#multiplesclerosis #MS

#MEDIA – We are pleased to announce that the phase III study met its primary endpoint, significantly improving progression-free survival for people with second-line or later relapsed or refractory #FollicularLymphoma #Hematology spkl.io/60157rk3h $ROG $RHHBY

Finding faint molecular clues early is critical for cancer research. Sequencing by expansion (SBX) technology can help researchers detect traces of circulating tumor DNA (ctDNA) to help reveal how tumors grow, change and react to treatment.

Learn how: go.roche.com/xgensbx #NGS #Genomics #Innovation #MakeSpaceWithSBX #RocheSBX

#MEDIA – We’re pleased to share positive Phase III data from our collaborator MediLink’s study in Chinese patients with relapsed small-cell #LungCancer, being presented at #WCLC26. Read more here: spkl.io/60187rEA2 $ROG $RHHBY